Apple Restores Telegram to App Store After Content Policy Violation 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Telegram Restored on Apple App Store After Temporary Removal 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Jetstar to Charge for Overhead Cabin Bags From February 
NEW YORK, March 28, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased MiMedx Group Inc. ("MiMedx") (NASDAQ:MDXG) securities between March 7, 2013 and February 19, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/mimedx-group-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) MiMedx was engaged in a "channel-stuffing" scheme designed to inappropriately recognize revenue that had not yet been realized; (ii) the Company lacked adequate internal controls over financial reporting; and (iii) that as a result of the foregoing, MiMedx’s publicly disseminated financial statements were materially false and misleading. On February 20, 2018, MiMedx announced that it would postpone the release of its financial results and Form 10-K filing for the year ended December 31, 2017. MiMedx stated it had engaged “independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to the allegations regarding certain sales and distribution practices at the Company.” Following this news, shares of MiMedx fell from a close of $14.47 per share on February 16, 2018 to a close of $8.75 on February 20, 2018.
If you suffered a loss in MiMedx you have until April 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/mimedx-group-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
